Trials / Completed
CompletedNCT00474760
Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors
Phase 1, Open Label, Multiple Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP 751,871 In Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 9 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1 study of anti-IGF-IR CP-751,871 in patients with solid tumors currently enrolling patients 9 years old and older with Ewing's sarcoma family of tumors (Ewing's, PNET and Askin's).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CP-751,871 | Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2011-01-01
- Completion
- 2012-10-01
- First posted
- 2007-05-17
- Last updated
- 2013-12-17
- Results posted
- 2013-12-17
Locations
3 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT00474760. Inclusion in this directory is not an endorsement.